JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive: For instance, JAK2 is activated following binding of hematopoietic growth factors to their receptors during CML leukemogenesis; it has been reported that the treatment with nilotinib and ruxolitinib leads to eradication of primary human CML LSCs in vitro [21], and ongoing clinical trials are attempting to improve outcomes of CML patients [38].